Actionable news
0
All posts from Actionable news
Actionable news in ABBV: ABBVIE Inc,

AbbVie (ABBV) Stock Plummets on FDA Warning about Hep C Treatments

NEW YORK (TheStreet) -- AbbVie (ABBV - Get Report) stock is lower by 10.72% to $48.06 in late afternoon trading on Thursday, after the Food and Drug Administration issued a warning about the drug maker's hepatitis C treatments.

The treatments Viekira Pak and Technivie "can cause serious liver injury," particularly for patients with an underlying advanced liver disease, the FDA said in a statement.

The FDA is mandating that manufacturer AbbVie include information about the adverse safety risks on the Viekira Pak and Technivie drugs' labels.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks with serious upside potential in the next 12-months. Learn more.

AbbVie identified cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who took the medications, according to the statement.

Some of the cases resulted in liver transplantation or death, the FDA notes.

Separately, TheStreet Ratings team rates ABBVIE INC as a Hold with a ratings...


More